Iovance stock ends Q3 up 256% after raising 2026 guidance on cancer therapy demand
Iovance Biotherapeutics finished Q3 as America's top-performing mid-cap stock, up 256%, after lifting its 2026 revenue guidance to $410-420 million on accelerating demand for its Amtagvi cancer therapy.